EGFR and head and neck cancer: A phase 1/2a, open-label, multicenter clinical study using Epidermal growth factor receptor (EGFR)-targeted cetuximab-IR700 (RM-1929) in patients with locoregional recurrent head and neck cancer demonstrated good tolerability and clinically meaningful response and survival [22].